Gastrointestinal Disorder Management

Introduction to Therapy

For patients with gastrointestinal symptoms, transitioning from benzodiazepines to targeted therapies such as antispasmodics, neuromodulators, or condition-specific medications is recommended by the American Gastroenterological Association, due to the high risk of dependence and adverse effects associated with long-term benzodiazepine use 1, 2, 3, 4
Short-term benzodiazepine use may help stabilize acute symptoms, but is not suitable for long-term management, as suggested by the American Academy of Child and Adolescent Psychiatry and the American Gastroenterological Association 1, 4

Benzodiazepines may be used as adjuncts to help stabilize acutely psychotic or agitated patients, but their use should be limited to the acute phase (1-2 weeks maximum) and ideally used at the lowest effective dose, as suggested by the American Academy of Child and Adolescent Psychiatry 4

For IBS with pain, tricyclic antidepressants (TCAs) are first-line, with a relative risk of 0.53 (95% CI 0.34-0.83), as recommended by the American Gastroenterological Association 3
For IBS with diarrhea, consider alosetron, eluxadoline, or antispasmodics, according to the American Gastroenterological Association 2, 3
For IBS with constipation, linaclotide (290 mcg daily) is recommended for pain relief, as suggested by the American Gastroenterological Association 3
For functional dyspepsia, PPI therapy is recommended for epigastric pain, according to the European Society of Gastrointestinal Endoscopy 5

For visceral pain, low-dose TCAs (e.g., amitriptyline 10-25 mg) are recommended, with evidence from the American Gastroenterological Association and the European Society of Gastrointestinal Endoscopy 3, 6
For anxiety with GI symptoms, consider SSRIs if mood disorder is present, as suggested by the European Society of Gastrointestinal Endoscopy 6
For pain unresponsive to TCAs, SNRIs (duloxetine, venlafaxine) may be considered, according to the European Society of Gastrointestinal Endoscopy 6
Psychological support or cognitive behavioral therapy may be beneficial for anxiety component, as suggested by the European Society of Gastrointestinal Endoscopy 6

For abdominal pain, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) are recommended, with evidence from the American Gastroenterological Association 3
For diarrhea-predominant symptoms, antispasmodics or alosetron may be considered, according to the American Gastroenterological Association 2
For constipation-predominant symptoms, linaclotide is recommended, as suggested by the American Gastroenterological Association 2, 3
For dyspepsia with epigastric pain, PPI therapy is recommended, according to the European Society of Gastrointestinal Endoscopy 5
Olanzapine may be used for breakthrough nausea/vomiting, as recommended by the American Society of Clinical Oncology and the National Comprehensive Cancer Network 7

Benzodiazepines can be classified based on their half-life, as shown in the following table:

Lorazepam and oxazepam are preferred in patients with hepatic dysfunction due to minimal accumulation of active metabolites and more predictable metabolism, according to the American Association for the Study of Liver Diseases 9, 10
Elderly patients have heightened sensitivity to benzodiazepine side effects, and use should be carefully considered due to increased sensitivity, higher risk of falls, cognitive impairment, and delirium, as noted by the American Geriatrics Society and the American College of Clinical Pharmacology 11, 12
The American Society of Clinical Oncology recommends using the lowest effective dose for the shortest duration possible, ideally for anxiety or insomnia management, and considering non-pharmacological alternatives for long-term management 13
Regular reassessment of the continued need for benzodiazepines is crucial, with evaluation at least every 2-4 weeks, and monitoring parameters should include cognitive function, balance and gait, falls risk, and signs of dependence or tolerance, as recommended by the American Medical Association 12
Abrupt discontinuation of benzodiazepines can cause severe withdrawal symptoms, highlighting the need for careful tapering and monitoring, and a tapering plan should be implemented if benzodiazepines are used for more than 6 weeks, with a gradual taper over 2-12 weeks, to minimize the risk of withdrawal symptoms, as suggested by the Substance Abuse and Mental Health Services Administration 11

For insomnia, cognitive behavioral therapy for insomnia (CBT-I) is recommended as first-line treatment, according to the American Society of Clinical Oncology, and if pharmacotherapy is needed, shorter-acting benzodiazepines or non-benzodiazepine medications may have fewer long-term risks for short-term use 13
The American Academy of Sleep Medicine recommends considering non-pharmacological alternatives for long-term management of anxiety or insomnia 13